Next Investors logo grey

Creso closer than ever to tapping billion-dollar Canadian cannabis industry

|

Published 21-JUN-2018 14:13 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

In the wake of the Canada’s recent legalisation of recreational cannabis nationwide, Creso Pharma (ASX:CPH) has said that it welcomes this decision with open arms.

The landmark bill and the historic vote passed on Tuesday June 18, and will allow Canadians to legally buy and consume cannabis. The Cannabis Act was approved by the Senate 52-29 after already passing the House of Commons in May this year.

Critically, this marks an end of 90 years of prohibition. It also makes Canada the second country in the world — and the first G7 nation — to fully legalise cannabis for recreational consumption and open up sale and distribution to both domestic and international markets.

An official date for the law to officially come into place has now been confirmed by Prime Minister Justin Trudeau to be October 17.

CPH, which has its corporate eye on the budding global cannabis market, has already established a considerable presence in North America — the passing of this law will enable further substantial opportunity for product growth and uptake.

In 2017, CPH became the only Australian cannabis company with direct exposure to the world’s largest legal marijuana market via its acquisition of Nova Scotia-based medicinal cannabis applicant, Mernova Medicinal Inc.

This deal delivered on CPH’s strategy to establish a Canadian presence, as well as its pursuit of opportunities in the global medicinal cannabis space, with added exposure to the ample recreational cannabis market.

Timing of this new legislation could scarcely be more apt for CPH, given that construction of its 20,000 square foot medicinal cannabis growing facility is currently underway and making sound progress, with completion expected in Q3 2018. This will enable CPH to vertically integrate its production chain, capitalising on the sizeable market opportunity of both medical and recreational marijuana.

Although how much of the market CPH is able to attract remains speculative and investors should take all publicly available information into account and seek professional financial advice before making an investment decision.

The new law allows the Canadian federal government to license producers and regulate how they grow, sell and distribute cannabis. Adults aged 18 and over will be permitted to possess up to one ounce of cannabis for recreational use, and grow up to four cannabis plants.

Cannabis-infused edibles will also be legal within one year of the law’s implementation — a market Creso is targeting with its cannaQIX and cannapeal ranges. CPH has also developed a range of terpene-infused premium Swiss chocolates — a major offering into the cannabis-infused edibles market.

Further cementing its position in Canada, CPH last week announced its appointment of John Griese as COO for the Americas. Griese brings expansive expertise in the North American cannabis space, and will help crystallise CPH’s presence in the region.

Canada is expected to be a US$6.5 billion ($8.7 billion) industry by 2020, according to research by Canadian Imperial Bank of Commerce (CIBC). That’s more than the US$5.1 billion Canadians spent on alcoholic spirits in 2017, and it’s approaching wine sales.

In 2017, US$2.25 billion was raised across 206 cannabis companies in Canada. In the first quarter of 2018 alone, over US$1.35 billion was raised across 96 Canadian cannabis companies, reflecting significant forecasted growth and demand.

More equity capital has been raised for cannabis companies in Canada than anywhere else in the world, with over 50 companies listed on the Canadian stock exchange.

CPH CEO, Dr Miri Halperin Wernli, said: “The full legalisation of cannabis use in Canada is really positive news. Creso has been growing its presence in Canada as we believe it offers huge potential for the uptake of our products. This law signals a great future for the industry in this market and we hope other countries will follow suit."

“Not only is it positive news for the industry, but it will also make the purchasing of cannabis safer for Canadians by providing legal licensed businesses where consumers know what they’re buying,” she said. “It will allow for better quality control and more public health awareness campaigns, whilst depriving organised crime of money and making it harder for children to access."

“Canada is demonstrating great leadership on cannabis policy. It is setting an example not only for the U.S., where reform is already progressing at the federal level, but for many other countries around the world, where there has been far too little debate on the subject."

“Cannabis prohibition is a failed U.S. policy experiment that was replicated by countries around the world. It has caused far more problems than it has solved, and governments should now follow Canada’s example by revisiting their cannabis policies and exploring alternatives,” Halperin Wernli noted.



General Information Only

This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.